Spironolactone. I. Disposition and metabolism

Clinical Pharmacology and Therapeutics

Volumn 19, Issue 2, 1976, Pages 158-169

  Karim, A ^a,b   Zagarella, J ^a,b   Hribar, J ^a,b   Dooley, M ^a,b  

^a PFIZER INC   (United States)

^b Techni Med Consultants Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENONE; SPIRONOLACTONE; CANRENOIC ACID; GLUCURONIDE;

ADULT; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RADIOACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG URINE LEVEL; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; SERUM; SPIRONOLACTONE H 3; THEORETICAL STUDY; URINE;

ADULT; CANRENONE; DRUG STABILITY; ERYTHROCYTES; FECES; HALF-LIFE; HUMAN; IN VITRO; MALE; PROTEIN BINDING; SPIRONOLACTONE; TIME FACTORS;

EID: 0017262778     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt1976192158     Document Type: Article

References (47)